VIDEO: Immunomodulatory adjustments do not impact COVID-19 vaccine immunogenicity
Click Here to Manage Email Alerts
DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.
At a poster session presented at the Congress of Clinical Rheumatology East, Andrew Laster, MD, of the Arthritis & Osteoporosis Clinic of the Carolinas, stated that he and colleagues found that holding JAK inhibitors, lowering methotrexate dose or altering vaccine timing to accommodate rituximab or abatacept does not impact COVID-19 vaccine immunogenicity in patients with AIIRD. The data have also been published in a research letter in RMD Open.
“We’ve learned an awful lot about COVID-19 in the last 2 years, but one of the things we are really unsure of, and remains unclear, is what to do with our immunomodulatory drugs in people who have rheumatic disease,” Laster told Healio. “As evidence of that, there are conflicting recommendations from ACR and EULAR.”
In their research, Laster and colleagues examined whether adjustments to immunomodulatory drugs impacted seroconversion rates following the COVID-19 vaccination.
“And what we found is that it didn’t,” Laster said. “Even though our criteria were more stringent than ACR, we couldn’t see that making any of these recommended adjustments had any effect on the seroconversion rate.”
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts